Carlo Lazzaro

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 17

Top Venues

Expert review of pharmacoeconomics & outcomes research

Therapeutic advances in medical oncology

The European journal of health economics : HEPAC : health economics in prevention and care

Clinical ophthalmology (Auckland, N.Z.)

Studio di Economia Sanitaria

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Studio di Economia Sanitaria Feb 05 1994

Italy

Research Director :: Health economics - Research and consulting

Publications

Carlo Lazzaro
On cost-effectiveness analysis, quality-adjusted life years, and cost-effectiveness threshold values of gemcitabine plus nab-paclitaxel versus gemcitabine alone in metastatic pancreatic cancer in the French setting. Therapeutic advances in medical oncology 16 (2024)
Carlo Lazzaro
On cost-effectiveness analysis, quality-adjusted life years, and cost-effectiveness threshold values of gemcitabine plus nab-paclitaxel versus gemcitabine alone in metastatic pancreatic cancer in the French setting. Therapeutic advances in medical oncology 16 (2024)
Carlo Lazzaro
Letter to the Editor: Lazzaro responds to Kennedy et al. The European journal of health economics : HEPAC : health economics in prevention and care (2024)
Mickaël Hiligsmann, Mitchell P DeKoven, Riddhi Doshi, Carolyn Gotay, Carlo Lazzaro, Jayashri Sankaranarayanan, Rayya Hajjar
Expert review of pharmacoeconomics and outcomes research: high impact articles from 2023. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Mickaël Hiligsmann, Mitchell P DeKoven, Riddhi Doshi, Carolyn Gotay, Carlo Lazzaro, Jayashri Sankaranarayanan, Rayya Hajjar
Expert review of pharmacoeconomics and outcomes research: high impact articles from 2023. Expert review of pharmacoeconomics & outcomes research (2024)
Carlo Lazzaro, Cécile van Steen, Giorgio Ghirelli, Matteo Sacchi, Dario Sisto, Maurizio Uva, Luigi Varano, Luigi Angelillo
A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis. Expert review of pharmacoeconomics & outcomes research (2023)
Carlo Lazzaro, Cécile van Steen, Giorgio Ghirelli, Matteo Sacchi, Dario Sisto, Maurizio Uva, Luigi Varano, Luigi Angelillo
A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis. Expert review of pharmacoeconomics & outcomes research 23 (2) (2023)
Carlo Lazzaro, Cécile van Steen, Giorgio Ghirelli, Matteo Sacchi, Dario Sisto, Maurizio Uva, Luigi Varano, Luigi Angelillo
A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis. Expert review of pharmacoeconomics & outcomes research 23 (2) (2023)
Carlo Lazzaro, Nicola Amedeo Mazzanti, Silvia Rossi, Fabio Parazzini
Inebilizumab for neuromyelitis optica spectrum disorder in Italy: a budget impact model. Expert review of pharmacoeconomics & outcomes research (2023)
Carlo Lazzaro, Cécile van Steen, Giorgio Ghirelli, Matteo Sacchi, Dario Sisto, Maurizio Uva, Luigi Varano, Luigi Angelillo
A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis. Expert review of pharmacoeconomics & outcomes research (2022)
Carlo Lazzaro, Cécile van Steen, Florent Aptel, Cédric Schweitzer, Luigi Angelillo
Cost-Utility Analysis of STN1013001, a Latanoprost Cationic Emulsion, versus Other Latanoprost Formulations (Latanoprost) in Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease in France. Journal of ophthalmology 2022 (2022)
Carlo Lazzaro, Roberto Bergamaschi, Mauro Zaffaroni, Rocco Totaro, Damiano Paolicelli
Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing-remitting multiple sclerosis in Italy. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 43 (8) (2022)
Carlo Lazzaro, Cécile van Steen, Stephan Billeit, Heinrich Frauenknecht, Christopher Kallen, Stefan Pfennigsdorf, Ulrich Thelen, Luigi Angelillo
Cost-Utility Analysis of a Latanoprost Cationic Emulsion (STN1013001) versus Other Latanoprost in the Treatment of Open-Angle Glaucoma or Ocular Hypertension and Concomitant Ocular Surface Disease in Germany. Clinical ophthalmology (Auckland, N.Z.) 16 (2022)
Carlo Lazzaro
Letter to the Editor: Lazzaro responds to Rodríguez‑Sánchez et al. The European journal of health economics : HEPAC : health economics in prevention and care (2022)
Carlo Lazzaro, Luca Castagna, Francesco Lanza, Daniele Laszlo, Giuseppe Milone, Luca Pierelli, Riccardo Saccardi
Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis. Bone marrow transplantation 56 (8) (2021)
Carlo Lazzaro
Lazzaro responds to Pouwels et al. Breast cancer research and treatment 190 (1) (2021)
Carlo Lazzaro, Carlo Barone, Francesco Caprioni, Stefano Cascinu, Alfredo Falcone, Evaristo Maiello, Michele Milella, Carmine Pinto, Michele Reni, Giampaolo Tortora
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. Expert review of pharmacoeconomics & outcomes research 18 (4) (2018)

Carlo Lazzaro.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Carlo Lazzaro